INmune Bio Inc (INMB) — Cash Flow-to-Debt Ratio
INmune Bio Inc (INMB) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2026, meaning its operating cash flow of $-6.58 Million could theoretically repay -1% of its total liabilities ($6.48 Million) in one year. See financial flexibility index of INmune Bio Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
INmune Bio Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for INmune Bio Inc across 11 annual periods. For the full cash flow conversion analysis, see INmune Bio Inc (INMB) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for INmune Bio Inc (2015–2025)
Year-by-year debt coverage analysis for INmune Bio Inc. Check INmune Bio Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.56x | $-22.58 Million | $8.83 Million | ▲ +42.8% |
| 2024 | -4.47x | $-33.36 Million | $7.46 Million | ▼ -603.6% |
| 2023 | -0.64x | $-11.98 Million | $18.86 Million | ▲ +39.3% |
| 2022 | -1.05x | $-22.69 Million | $21.69 Million | ▲ +27.6% |
| 2021 | -1.45x | $-28.50 Million | $19.72 Million | ▲ +69.3% |
| 2020 | -4.70x | $-8.94 Million | $1.90 Million | ▲ +24.9% |
| 2019 | -6.26x | $-5.38 Million | $860.54K | ▼ -150.3% |
| 2018 | -2.50x | $-2.06 Million | $823.77K | ▼ -1.6% |
| 2017 | -2.46x | $-761.83K | $309.72K | ▼ -365.6% |
| 2016 | -0.53x | $-317.38K | $600.81K | ▲ +10.3% |
| 2015 | -0.59x | $-18.12K | $30.75K | — |